The Zimulti Acomplia Report

Now that a promising new prescription weight loss drug, rimonabant, it is today available in the U.K., Germany and 44 other countries, the launch of the most anticipated weight-loss Drug since Fen-phen is generating …

The year-long Rimonabant in Obesity-Diabetes study, a multi-center trial which enrolled 1,000 obese patients with type 2 diabetes, will be the last of the four major Acomplia studies to report trial results before U.S. and European …